Neurocentrx Pharma, one of Equity Gap’s portfolio companies, has this week announced a new and exciting stage in its journey: developing the first FDA-approved oral ketamine prescription for severe depression, offering a safe, regulated option for at-home care.
We’re pleased to be part of a strong syndicate of long-standing investors and charitable trusts – alongside Scottish Enterprise, Neo Kuma Ventures, o2h Ventures, Meltwind Advisory LLP, Old College Capital, Edinburgh Innovations and the Wellcome Trust – backing Neurocentrx as it scales its vision.
This is a critical step toward establishing a new care standard for depression, an area still poorly addressed by existing treatments. We look forward to Neurocentrx Pharma Ltd’s upcoming announcements on leadership, clinical collaborations, and further studies.
